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OBJECTIVE — Previous observational studies have found an increased risk of acute pancre-
atitis among type 2 diabetic patients. However, limited information is available on this associa-
tion and speciﬁcally on the role of antidiabetic treatment. Our aim, therefore, was to further
assess the risk of acute pancreatitis in adult patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — We performed a population-based case-
control analysis nested in a cohort of 85,525 type 2 diabetic patients and 200,000 diabetes-free
individuals from the general population using data from The Health Improvement Network
database. Subjects were followed up to ascertain incident cases of acute pancreatitis.
RESULTS — We identiﬁed 419 cases of acute pancreatitis, 243 in the general population and
176 in the diabetes cohort. Incidence rates were 30.1 and 54.0 per 100,000 person-years in the
general population and the diabetes cohort, respectively. In the cohort analysis, the adjusted
incidencerateratioofacutepancreatitisindiabeticpatientsversusthatinthegeneralpopulation
was 1.77 (95% CI 1.46–2.15). The magnitude of this association decreased with adjustment for
multiple factors in the nested case-control analysis (adjusted odds ratio 1.37 [95% CI 0.99–
1.89]). Furthermore, we found that the risk of acute pancreatitis was decreased among insulin-
treated diabetic patients (0.35 [0.20–0.61]).
CONCLUSIONS — Type 2 diabetes may be associated with a slight increase in the risk of
acute pancreatitis. We also found that insulin use in type 2 diabetes might decrease this risk.
Further research is warranted to conﬁrm these associations.
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A
cute pancreatitis is deﬁned as an
acute inﬂammatory process of the
pancreas. The incidence of acute
pancreatitis in the general population
shows geographical variation. Incidence
rates reported in the literature range be-
tween 4 and up to 100 cases per
100,000 person-years in the western
world (1–3). Data from western countries
suggest that the incidence of acute pan-
creatitis has been increasing over the last
40 years (3).
The reason for this increase is un-
known. However, a concurrent trend has
been the rapid, worldwide increase in
type 2 diabetes and obesity. Several clin-
icalfactorsassociatedwithtype2diabetes
and obesity are known or putative risk
factors for acute pancreatitis (e.g., gall-
stone disease). Therefore, it can be hy-
pothesized that in type 2 diabetic patients
the risk of acute pancreatitis might be
higher than that for the general popula-
tion(2).Studiesexploringwhetherdiabe-
tes or antidiabetic treatment may act as
risk factors for the development of acute
pancreatitishavebeenlimitedsofar(2,4–
6). Three observational studies reported
an approximately two- to threefold in-
creased risk of acute pancreatitis among
diabetic patients (2,4,5). The purpose of
this study was to further assess the risk of
acute pancreatitis in association with type
2 diabetic patients and antidiabetic
treatment.
RESEARCH DESIGN AND
METHODS— This population-based
cohort study with a nested case-control
analysis was based on information from
The Health Improvement Network
(THIN). THIN is a U.K. longitudinal pri-
mary care medical record database that
includes diagnostic and prescribing data
recorded by general practitioners as part
of their routine clinical care. The popula-
tion in THIN is representative of the gen-
eral population in the U.K.
The source population included all
individuals aged 20–79 years in THIN
enrolledforatleast2yearswiththeirgen-
eral practitioner, who had the ﬁrst pre-
scription ever recorded in the computer
ﬁles 1 year before entering the study
andatleastonehealthcontactinthelast2
years. The study period was from 1 Janu-
ary 1996 to 31 December 2006. We ex-
cluded all individuals with a history of
cancer (other than nonmelanoma skin
cancer)orpancreaticdiseasebeforeenter-
ingthestudy.Individualsaged70years
with a follow-up 1 year and less than
two health contacts during their fol-
low-up period were removed because
data completeness is most likely seriously
deﬁcient in this subgroup. We identiﬁed
two cohorts within this source popula-
tion: the type 2 diabetes cohort and the
(diabetes-free)generalpopulationcohort.
We ascertained all patients within the
study base with a READ code of diabetes
recorded in the database. Based on type-
speciﬁc READ codes (i.e., those that de-
note explicitly the type of diabetes), the
age at diagnosis, and the lifetime history
ofantidiabeticpharmacologicaltreatment
we were able to classify the initial 92,701
patients with a recorded diagnosis of dia-
betes into 7,176 (7.74%) patients with
type 1 and 85,525 (92.26%) with type 2
diabetes. The latter comprised the type 2
diabetes cohort (Fig. 1).
The general population cohort in-
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sampled from the source population and
frequency-matched by age, sex, and cal-
endar year to the diabetes cohort. The
same eligibility criteria as for the diabetes
cohort were applied with the additional
condition that patients had to be free of a
recorded diagnosis of diabetes.
Follow-up for acute pancreatitis
We followed all members from the diabe-
tes and the general population cohort
from the date when an individual met all
eligibility criteria until the earliest occur-
renceofoneofthefollowingendpoints:a
recorded diagnosis of acute pancreatitis,
cancer,hisorher80thbirthday,death,or
the end of the study period. We reviewed
the computerized patient proﬁles with
freetextcommentsofallindividualsiden-
tiﬁed as potentially having cases of pan-
creatitis. After this manual review of all
potential cases, we classiﬁed cases as “not
conﬁrmed” (and subsequently excluded
them from the study) in situations in
which acute pancreatitis was initially sus-
pected but ruled out later on, and in indi-
viduals who met an exclusion criterion
(i.e., cancer or prevalent case of pancre-
atic disease). All remaining cases were
considered as “conﬁrmed” incident cases,
most cases (88%) being well docu-
mented; i.e., the episode of acute pancre-
atitis either included a documented
emergency admission and/or hospitaliza-
tion or the diagnosis had been made by a
specialist.
For a random sample of 50 case sub-
jects, we also sent out a questionnaire to
the patient’s general practitioners to con-
ﬁrmthediagnosisandtoprovideallavail-
able additional data related to that event.
We received valid information (question-
naires and additional clinical documents)
for 44 case subjects, corresponding to a
88% response rate.
Statistical analyses
Cohort analysis. Person-time at risk in
each study cohort was classiﬁed across
strata by age, sex, and calendar year. Age-
and sex-speciﬁc incidence rates of acute
pancreatitiswerecalculatedusingthecor-
responding person-time at risk in each
cohort as denominator.
Crudeandadjustedincidenceratera-
tios (IRRs) with 95% CIs associated with
diabetes were computed using a Poisson
regression model with age, sex, and cal-
endar year included in the model. Poten-
tialinteractionswerestudiedbyincluding
thesevariablesinthemodelasinteraction
terms.
Nested case-control analysis. In addi-
tion, a nested case-control analysis was
performed to evaluate in more detail the
role of diabetes and of antidiabetic drugs
on the risk of acute pancreatitis. The in-
dividuals with conﬁrmed cases of acute
pancreatitis from both cohorts were used
ascasesubjectsandtheirdateofdiagnosis
was used as the index date.
Control subjects were randomly sam-
pled from the two study cohorts in which
pancreatitis case subjects were ascer-
tained. A group of 5,000 control subjects
was randomly selected from the list of el-
igible person-time and frequency-
matched to the case subjects on sex, same
age (1 year), and calendar year.
For all case and control subjects we
ascertained demographic (age, sex,
Townsend deprivation index [7,8], and
BMI) and lifestyle factors (e.g., smoking
and alcohol intake) as well as general co-
morbidity (e.g., chronic conditions and
previous gastrointestinal diseases) at the
index date. In addition, weascertained ex-
posure to antidiabetic drugs using separate
exposure variables for insulin, metformin,
sulfonylureas, thiazolidinediones, and
other antidiabetic drugs (i.e., acarbose, re-
paglinide, and nateglinide) and other com-
mon drugs or drug classes including
antibiotics, antidepressants, corticoste-
roids, acid-suppressing drugs, nonsteroidal
anti-inﬂammatorydrugs(NSAIDs),aspirin,
paracetamol, antihypertensive agents,
lipid-lowering drugs, and hormone re-
placement therapy. Individuals were
classiﬁed as current users if they were
taking the drug at the index date or had
taken it within the previous 30 days.
Those not currently exposed but who
had used the drug within the year be-
fore the index date were classiﬁed as
past users. Everyone else was classiﬁed
as nonuser. We also explored the effect
of drug duration (1 year, 1–3 years,
and 3 years) on the risk of acute
pancreatitis.
Unconditional regression analyses
were used to assess odds ratios (ORs) to-
gether with 95% CIs. The fully adjusted
model included the matching variables
age and sex and the following predictors
of acute pancreatitis: smoking status, al-
cohol intake, ischemic heart disease, pre-
viousgastrointestinaldisease,exposureto
antidiabetic drugs, antibiotics, acid-
suppressing drugs, NSAIDs (including
aspirin and coxibs), paracetamol, and
antihypertensive drugs, BMI, and
Townsenddeprivationindex.Allanalyses
weredoneusingStataSE10.0(StataCorp,
College Station, TX).
RESULTS
Cohort analysis
A total of 85,525 patients with type 2
diabetes were included for the cohort
analyses together with the 200,000 fre-
quency-matched individuals from the
generalpopulation.TheaverageSDage
at start date in the type 2 diabetes and the
general population cohort was 61.2 
11.4 and 59.5  12.8 years, respectively;
43.7% of subjects in the diabetes and
43.5% in the general population cohort
were female. The total amount of fol-
low-uptimewas325,990person-yearsin
Figure 1—Study cohorts and acute pancreatitis ascertainment.
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years in the general population cohort,
corresponding to an average follow-up
time of 3.8 and 4.0 years, respectively.
During follow-up, we identiﬁed a total of
456 potential cases of acute pancreatitis,
261 in the general population and 195 in
the diabetes cohort.
After manual review of the patients’
computerized proﬁles, we classiﬁed 35
cases as not conﬁrmed cases (7.7%). The
remaining 421 cases were classiﬁed as
conﬁrmed cases.
In the validation study, 2 of the 44
casesinindividualsforwhomwereceived
valid information were considered as not
conﬁrmed by the general practitioners.
This resulted in a conﬁrmation rate of
95.5% in the validation study. These 2
not conﬁrmed cases were subsequently
excluded, leaving 419 cases of acute pan-
creatitis included in the ﬁnal analyses
(243 cases in the general population and
176casesinthediabetescohort).Thecor-
responding crude incidence rate of acute
pancreatitis was 30.1 per 100,000 per-
son-years in the general population and
54.0 per 100,000 person-years in the di-
abetescohort.Incidenceratesstratiﬁedby
age and sex for the diabetic and the gen-
eral population cohort are presented in
Table 1.
These results translate into a 79% in-
creasedriskofaﬁrst-everepisodeofacute
pancreatitis among type 2 diabetic pa-
tients compared with the general popula-
tion (crude IRR 1.79 [95% CI 1.48–
2.18]). Because the two cohorts were
frequency matched, we obtained very
similar results when we estimated the
age-, sex-, and calendar year–adjusted
IRR by ﬁtting a Poisson regression model
(1.77 [1.46–2.15]).
Increasing age was associated with a
higher risk of acute pancreatitis in the
overallcohort.Comparedwiththoseaged
40 years, the risk of acute pancreatitis
was increased in those aged 40–59, 60–
69, and 70 years by 17, 20, and 50%,
respectively (Ptrend  0.02).
Furthermore, we explored the poten-
tial effect modiﬁcation of the association
between diabetes and acute pancreatitis
by age. We found a signiﬁcant trend to-
ward a decreasing association between
diabetes and acute pancreatitis with in-
creasing age (P  0.019). We also evalu-
ated whether sex could modify the
association between diabetes and acute
pancreatitis,butthecorrespondingstatis-
tical test was not signiﬁcant.
Nested case-control analysis
Afteradjustmentforvariousdemographic
and lifestyle variables, comorbidities, and
drug exposure, patients with type 2 dia-
betes had a nonsigniﬁcantly increased
risk of acute pancreatitis compared with
those free of diabetes (adjusted OR 1.37
[95%CI0.99–1.89])(Table2).Whenwe
analyzed separately the risk associated
withincidentdiabetes(diabetesﬁrstdiag-
nosed during the study period) and prev-
alent diabetes (diabetes ﬁrst diagnosed
before the study period), the adjusted
ORs were virtually the same (1.38 [0.98–
1.94] and 1.34 [0.90–2.01], respec-
tively). Furthermore, to explore the
possibility of an increased risk of acute
pancreatitis around the time of the ﬁrst
diagnosis of diabetes, we further divided
our cohort of incident diabetic patients
according to the time elapsed since the
ﬁrst diagnosis of diabetes. During the 1st
year after the diagnosis of diabetes, the
risk was somewhat higher (1.61 [1.00–
2.60])thanthereafter(1.26[0.85–1.88]).
This difference, however, did not reach
statistical signiﬁcance (P  0.38).
Among users of antidiabetic drugs,
current users of insulin were at a de-
creased risk of acute pancreatitis (ad-
justed OR 0.35 [95% CI 0.20–0.61])
compared with nonusers. Moreover, past
use of sulfonylureas was associated with a
signiﬁcant risk increase of acute pancre-
atitis compared with that for nonusers
(2.58 [1.34–4.96]). Otherwise, exposure
to antidiabetic drugs was not materially
associated with the risk of acute pancre-
atitis (Table 2).
We also explored the impact of treat-
ment duration among current antidia-
betic drug users (Table 3). A reduced risk
of acute pancreatitis was observed across
alldifferentstrataofinsulindurationwith
a similar magnitude of association, corre-
sponding to a 60–70% reduction in the
acute pancreatitis risk. Of interest, met-
formin and sulfonylureas, which overall
Table1—Incidencerateofacutepancreatitisbyageandsexinthegeneralpopulationwithout
diabetes and in type 2 diabetic patients (cohort analysis)
Age strata Person-years Cases
Incidence rate per 100,000
person-years (95% CI)
General population (n  200,000)
Women
20–39 years 25,300 5 19.8 (6.4–46.1)
40–59 years 105,655 22 20.8 (13–31.5)
60–69 years 105,824 27 25.5 (16.8–37.1)
70–79 years 116,742 41 35.1 (25.2–47.6)
Overall 353,521 95 26.9 (21.7–32.8)
Men
20–39 years 25,732 5 19.4 (6.3–45.3)
40–59 years 157,241 46 29.3 (21.4–39)
60–69 years 146,542 41 28.0 (20–37.9)
70–79 years 124,416 56 45.0 (34–58.4)
Overall 453,932 148 32.6 (27.5–38.3)
Total 807,453 243 30.1 (26.4–34.1)
Type 2 diabetes (n  85,525)
Women
20–39 years 5,105 4 78.4 (21.3–200.6)
40–59 years 40,585 21 51.7 (32–79.1)
60–69 years 45,377 27 59.5 (39.2–86.5)
70–79 years 50,057 22 43.9 (27.5–66.5)
Overall 141,125 74 52.4 (41.1–65.8)
Men
20–39 years 4,479 2 44.7 (5.4–161.3)
40–59 years 61,109 35 57.3 (39.8–79.6)
60–69 years 63,979 32 50.0 (34.2–70.6)
70–79 years 55,299 33 59.7 (41–83.8)
Overall 184,865 102 55.2 (44.9–66.9)
Total 325,990 176 54.0 (46.3–62.5)
IRRdiabetes 1.79 (1.48–2.18)*
*Unadjustedestimateofacutepancreatitisintype2diabeticpatientscomparedwiththegeneralpopulation.
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Case subjects Control subjects
Odds ratio (95% CI)
Univariate Adjusted*
n 419 5,000
Smoking
Nonsmoker 128 (30.5) 1,795 (35.9) 1 (referent) 1 (referent)
Smoker 71 (16.9) 623 (12.5) 1.60 (1.18–2.17) 1.48 (1.06–2.06)
Former smoker 175 (41.8) 1,909 (38.2) 1.29 (1.01–1.63) 1.14 (0.89–1.47)
Unknown 45 (10.7) 673 (13.5) 0.94 (0.66–1.33) 1.18 (0.81–1.72)
Alcohol use
Nondrinker 200 (47.7) 2,082 (41.6) 1 (referent) 1 (referent)
Between 1 and 7/week 92 (22.0) 1,236 (24.7) 0.77 (0.60–1.00) 0.86 (0.66–1.13)
Between 8 and 29/week 58 (13.8) 895 (17.9) 0.67 (0.50–0.91) 0.75 (0.54–1.03)
30/week 45 (10.7) 291 (5.8) 1.61 (1.14–2.27) 1.49 (1.02–2.18)
Unknown 24 (5.7) 496 (9.9) 0.50 (0.33–0.78) 0.72 (0.43–1.19)
Diabetes
No 243 (58.0) 3,489 (69.8) 1 (referent) 1 (referent)
Yes 176 (42.0) 1,511 (30.2) 1.67 (1.36–2.05) 1.37 (0.99–1.89)
Antidiabetic drugs
Insulin
Nonuse (366) 399 (95.2) 4,650 (93.0) 1 (referent) 1 (referent)
Current use (0–30) 19 (4.5) 328 (6.6) 0.68 (0.42–1.08) 0.35 (0.20–0.61)
Past use (31–365) 1 (0.2) 22 (0.4) 0.53 (0.07–3.94) 0.31 (0.04–2.43)
Metformin
Nonuse (366) 328 (78.3) 4,261 (85.2) 1 (referent) 1 (referent)
Current use (0–30) 75 (17.9) 655 (13.1) 1.49 (1.14–1.94) 0.81 (0.56–1.15)
Past use (31–365) 16 (3.8) 84 (1.7) 2.47 (1.43–4.27) 1.18 (0.62–2.25)
Sulfonylureas
Nonuse (366) 334 (79.7) 4,460 (89.2) 1 (referent) 1 (referent)
Current use (0–30) 69 (16.5) 474 (9.5) 1.94 (1.48–2.56) 1.25 (0.86–1.80)
Past use (31–365) 16 (3.8) 66 (1.3) 3.24 (1.85–5.65) 2.58 (1.34–4.96)
Thiazolidinediones
Nonuse (366) 396 (94.5) 4,864 (97.3) 1 (referent) 1 (referent)
Current use (0–30) 20 (4.8) 117 (2.3) 2.10 (1.29–3.41) 1.25 (0.72–2.16)
Past use (31–365) 3 (0.7) 19 (0.4) 1.94 (0.57–6.58) 1.23 (0.33–4.66)
Other antidiabetic drugs
Nonuse (366) 412 (98.3) 4,962 (99.2) 1 (referent) 1 (referent)
Current use (0–30) 4 (1.0) 27 (0.5) 1.78 (0.62–5.12) 1.23 (0.40–3.78)
Past use (31–365) 3 (0.7) 11 (0.2) 3.28 (0.91–11.82) 2.56 (0.61–10.66)
Gastrointestinal disease†
No 107 (25.5) 2,318 (46.4) 1 (referent) 1 (referent)
Yes 312 (74.5) 2,682 (53.6) 2.52 (2.01–3.16) 1.91 (1.50–2.45)
BMI
20–24 kg/m
2* 95 (22.7) 1,242 (24.8) 1 (referent) 1 (referent)
20 kg/m
2 15 (3.6) 164 (3.3) 1.20 (0.68–2.11) 1.13 (0.63–2.02)
25–29 kg/m
2 154 (36.8) 1,809 (36.2) 1.11 (0.85–1.45) 0.99 (0.75–1.31)
30 kg/m
2 131 (31.3) 1,337 (26.7) 1.28 (0.97–1.69) 0.92 (0.68–1.24)
Unknown 24 (5.7) 448 (9.0) 0.70 (0.44–1.11) 1.01 (0.60–1.72)
Paracetamol
Nonuse (366) 240 (57.3) 3,620 (72.4) 1 (referent) 1 (referent)
Current use (0–30) 105 (25.1) 732 (14.6) 2.16 (1.70–2.76) 1.65 (1.25–2.18)
Past use (31–365) 74 (17.7) 648 (13.0) 1.72 (1.31–2.26) 1.38 (1.02–1.86)
ACE inhibitors
Nonuse (366) 3,892 (77.8) 280 (66.8) 1 (referent) 1 (referent)
Current use (0–30) 978 (19.6) 124 (29.6) 1.76 (1.41–2.20) 1.37 (1.04–1.80)
Past use (31–365) 130 (2.6) 15 (3.6) 1.60 (0.93–2.77) 1.12 (0.61–2.04)
Data are n (%) unless otherwise indicated. *Adjusted for all variables included in the table plus age, sex, Townsend index, ischemic heart disease, and exposuret o
antibiotics,H2blockers,protonpumpinhibitors,NSAIDs(includingaspirinandcoxibs),andotherantihypertensivedrugs.†Includesgallstones,biliarytractdisease,
cholecystitis, gastroenteritis, abdominal pain, and others.
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pancreatitis, were associated with de-
creased and increased risks, respectively,
but only among long-term users of these
drugs. The other antidiabetic drugs stud-
ied (thiazolidinediones and others) were
notfoundtobeassociatedwithacutepan-
creatitis in any of these analyses although
their numbers were considerably smaller.
Among individuals with diabetes,
metformin and sulfonylureas were the
two most commonly prescribed drugs,
followed by insulin. Among control sub-
jects, a total of 73% of diabetic patients
were receiving speciﬁc antidiabetic drug
treatment at the index date. The remain-
ing 27% were not currently receiving an-
tidiabetic drug therapy. Treated diabetic
patientshadanadjustedORof1.19[95%
CI 0.91–1.55] for acute pancreatitis
compared with that for the general popu-
lation,whereasthosenotreceivingantidi-
abetic drug treatment (1.49 [1.06–2.08])
seemed to concentrate the overall in-
creased risk associated with diabetes.
However, this difference was not statisti-
cally signiﬁcant (P  0.21). In addition,
the risk of acute pancreatitis was signiﬁ-
cantly increased among current smokers,
those taking 30 units of alcohol per
week, individuals with a previous history
ofgastrointestinaldisease,andcurrentus-
ers of paracetamol and ACE inhibitors
(Table 2).
CONCLUSIONS— The results of
this study conﬁrm the excess risk of acute
pancreatitis associated with type 2 diabe-
tes previously reported in other observa-
tional studies (2,4,5). In fact, the cohort
analysis yielded a statistically signiﬁcant
77% increased risk of acute pancreatitis
associatedwithapriorhistoryofdiabetes.
This translates into 23 additional cases
for every 100,000 patients with diabetes
eachyear.However,themagnitudeofthis
association was reduced when it was ad-
justed for other risk factors in a multivar-
iate model and became borderline
signiﬁcant in the nested-case control
analysis.
This association of an increased risk
of acute pancreatitis and type 2 diabetes
seems more pronounced at younger ages
and has already been observed in a recent
retrospectivecohortstudybasedoninfor-
mationfromaU.S,healthclaimsdatabase
(2). We were also able to assess how an-
tidiabeticdrugsmightinﬂuencethisasso-
ciation. Interestingly, use of insulin and
long-term use of metformin were associ-
ated with a decreased risk of pancreatitis,
as opposed to long-term use of sulfonyl-
ureas,whichseemstoincreasetherisk.In
a previous case-control study, Blomgren
et al. (4) found that the sulfonylurea gly-
buride increased the risk of acute pancre-
atitis, but neither insulin nor metformin
seemedtolowertherisk.Infact,thereare
reports of cases of acute pancreatitis in
patients using metformin after an episode
ofacuterenalfailure(9,10).Tothebestof
our knowledge, this is the ﬁrst study sug-
gesting a reduced risk associated with
these antidiabetic drugs. We think it is
premature to propose potential mecha-
nismsbeforetheseﬁndingsarereplicated.
Overall, when we analyzed the risk of
pancreatitis among treated and not
treated diabetic patients separately, we
observed that the greatest risk appeared
among those without antidiabetic phar-
macotherapy, who represent a quarter of
our diabetic population. This result may
be partially due to a slight increased risk
ofacutepancreatitisimmediatelyafterthe
diagnosis of diabetes, although this as-
sumption could not be conﬁrmed in our
study.
Our data from the general population
cohort could replicate results from previ-
ous epidemiological studies showing that
the incidence of acute pancreatitis rises
withincreasingageandtendstobehigher
in men than women (1,11,12). Further-
more,theincidenceratefoundinthegen-
eral population is also in line with results
from a recent study from England (13).
Among other risk factors studied, we
found that previously reported risk fac-
tors such as smoking (5), alcohol use
(1,14), or use of ACE inhibitors (15,16)
were replicated in our study. Exposure to
paracetamol was also associated with an
increased pancreatitis risk as in previous
studies (15).
The current study has several
strengths. First, it is based on a large da-
tabasewithdocumentedhighdataquality
and completeness (17–19). Second, de-
tailed information on important lifestyle
factors, comorbidities, concomitant drug
therapies, and BMI was available. Third,
we reviewed the patient proﬁles of com-
puter-detectedpotentialcaseswithallad-
ditional information included in free text
Table 3—Risk of acute pancreatitis and duration of current use of antidiabetic drugs (nested
case-control analysis)
Case subjects Control subjects OR (95% CI)*
n 419 5,000
Insulin
Nonuse† 399 (95.2) 4,650 (93.0) 1 (referent)
Short duration (1 year) 7 (1.7) 82 (1.6) 0.41 (0.17–1.00)
Mid duration (1–3 years) 5 (1.2) 88 (1.8) 0.34 (0.13–0.91)
Long duration (3 years) 7 (1.7) 158 (3.2) 0.30 (0.13–0.68)
Metformin
Nonuse† 328 (78.3) 4,261 (85.2) 1 (referent)
Short duration (1 year) 26 (6.2) 213 (4.3) 0.88 (0.53–1.47)
Mid duration (1–3 years) 31 (7.4) 237 (4.7) 0.93 (0.58–1.49)
Long duration (3 years) 18 (4.3) 205 (4.1) 0.50 (0.28–0.91)
Sulfonylureas
Nonuse† 334 (79.7) 4,460 (89.2) 1 (referent)
Short duration (1 year) 13 (3.1) 125 (2.5) 0.81 (0.42–1.57)
Mid duration (1–3 years) 25 (6.0) 156 (3.1) 1.20 (0.70–2.03)
Long duration (3 years) 31 (7.4) 193 (3.9) 1.66 (1.01–2.74)
Thiazolidinediones
Nonuse† 396 (94.5) 4,864 (97.3) 1 (referent)
Short duration (1 year) 11 (2.6) 57 (1.1) 1.28 (0.61–2.68)
Mid duration (1–3 years) 7 (1.7) 46 (0.9) 1.19 (0.49–2.90)
Long duration (3 years) 2 (0.5) 14 (0.3) 1.27 (0.23–6.89)
Other antidiabetic drugs
Nonuse† 412 (98.3) 4,962 (99.2) 1 (referent)
Short duration (1 year) 1 (0.2) 9 (0.2) 1.24 (0.13–11.82)
Mid duration (1–3 years) 1 (0.2) 8 (0.2) 0.94 (0.11–8.14)
Long duration (3 years) 2 (0.5) 10 (0.2) 1.85 (0.34–10.10)
Data are n (%) unless otherwise indicated. *Adjusted for all variables included in the table plus those in the
fully adjusted model of Table 2. †Baseline category.
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arandomsamplebyaccessingtheoriginal
medical records available in general prac-
titionerofﬁces.Fourth,wecouldreplicate
results from other studies regarding the
association of various comorbidities
and/or exposures and the risk of acute
pancreatitis.
However, the study also has its limi-
tations. Although we adjusted our analy-
ses for various potential risk factors of
acute pancreatitis, it is possible that there
is still some residual confounding we did
not account for. Moreover, throughout
this report we present results for a large
number of factors including lifestyle, co-
morbidity, and drug therapies (as well as
different drug durations). This implicit
multiple testing could be inﬂating the
study-wide type I error. One should keep
this in mind, when interpreting these re-
sults, and even more so in the case of
subanalyses that do not belong to the
main purpose of the study. However, be-
cause of the exploratory nature of these
ﬁndings, we did not deem it necessary to
adjust for multiple comparisons.
In summary, we have shown that
type2diabetesmaybeassociatedwitha
slight increase in the risk of acute pan-
creatitis. We have also found that use of
insulin in type 2 diabetes might be as-
sociated with a reduced risk. Further
research is warranted to conﬁrm these
observed associations.
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